What is William Blair’s Estimate for NTLA Q2 Earnings?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at William Blair issued their Q2 2026 EPS estimates for shares of Intellia Therapeutics in a research report issued on Wednesday, March 26th. William Blair analyst M. Minter expects that the company will post earnings of ($1.22) per share for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

A number of other analysts have also commented on the company. Oppenheimer cut their price target on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. Chardan Capital reduced their price target on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a research report on Friday, February 28th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. The Goldman Sachs Group reissued a “sell” rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.56.

Intellia Therapeutics Stock Down 3.9 %

Intellia Therapeutics stock opened at $8.07 on Friday. The company has a 50 day moving average of $9.98 and a 200-day moving average of $13.77. Intellia Therapeutics has a twelve month low of $8.03 and a twelve month high of $28.18. The stock has a market capitalization of $835.38 million, a PE ratio of -1.48 and a beta of 1.97.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 29,000 shares of company stock worth $352,551. Company insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in NTLA. GF Fund Management CO. LTD. bought a new stake in shares of Intellia Therapeutics during the fourth quarter valued at approximately $25,000. Sterling Capital Management LLC increased its stake in Intellia Therapeutics by 866.2% during the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after purchasing an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC bought a new stake in Intellia Therapeutics during the 4th quarter valued at $40,000. Resona Asset Management Co. Ltd. acquired a new position in Intellia Therapeutics during the fourth quarter worth $43,000. Finally, Jones Financial Companies Lllp lifted its stake in shares of Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after buying an additional 2,280 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.